EXPERTS IN CANCER IMMUNOTHERAPY

WHO WE ARE

invIOs is a PRIVATE BIOTECH COMPANY focusing on discovering and developing next-generation cancer therapeutics.

We are pioneers in R&D of drug candidates targeting novel immune checkpoints, and in IMMUNE SYSTEM ACTIVATION.

We LAUNCHED IN 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics.

Our HIGHLY MOTIVATED TEAM of 35 people has deep expertise across the biotechnology value chain, with in-house expertise in R&D, clinical development, CMC, IP, scouting and more.

VISION AND MISSION

Our vision at invIOs is to transform patients’ lives with our SUSTAINABLE AND PROMISING TECHNOLOGIES.

Our mission is to become a LEADING GLOBAL BIOTECHNOLOGY COMPANY providing individualized treatments for patients.

Leadership Team

Peter Llewellyn-Davies

Chief Executive Officer, Chief Financial Officer (CEO/CFO)

More than 25 years of professional experience as Board member of companies such as Medigene AG, Shield Therapeutics plc, WILEX AG, Immunocore ltd. and Catherex Inc. as well as Advisory roles in companies to execute exit strategies. Peter is the founding president of BIOTECH AUSTRIA, the Austrian Biotechnology Association.

Romana Gugenberger

Chief Medical & Scientific Officer (CMSO)

Romana Gugenberger holds a PhD in Molecular Biology from the University of Vienna and worked several years at the Medical University of Vienna in the field of Cardiovascular Research and Tumor Biology. She joined APEIRON Biologics in 2010 supporting non-clinical and clinical projects. Currently she leads invIOs's APN401 clinical stage cell therapy project.

LEADERSHIP TEAM

Peter Llewellyn-Davies

Chief Executive & Financial Officer (CEO/CFO)

Romana Gugenberger

Chief Medical & Scientific Officer (CMSO)

SCIENTIFIC ADVISORS

Gottfried Baier

Professor Baier leads the Institute of Cell Genetics at the Medical University of Innsbruck's Department for Genetics and Pharmacology, where he also serves as Director of the Christian Doppler Laboratory for pharmacological cancer immunotherapy. His research achievements include the leading-edge discoveries of the central-staged PKC/Cbl-b and PKC/NR2F6 signaling pathways and their key role in the control of cancer immune surveillance. Professor Baier holds a PhD in medical microbiology and is the author of dozens of publications, reviews, abstracts and patents.

Thomas Bogenrieder

Professor Bogenrieder is Chief Medical Officer of Abbalos Therapeutics and an expert in clinical development of cancer immunotherapies. During a career spanning the private sector and academic research he has served as Group Leader Oncology at Boehringer Ingelheim in Vienna as well as Clinical Director Oncology at GSK's Oncology Center of Excellence. He holds a PhD from the University of Utrecht, an MD from Albert-Ludwigs-University in Freiburg, and is an Assistant Professor at the University of Tübingen.

Thorsten Füreder

Professor Füreder is a medical oncologist at the Medical University of Vienna. He is the program director for respiratory tract cancers (head and neck and lung cancer) and cancer of unknown primary at the Department of Medicine I, and serves as the chair of the immune-oncology tumor board. He has served as the principal investigator of several clinical Phase 1-3 trials and has published multiple international research articles. Professor Füreder holds an MD from the Medical University of Vienna and serves as president of the Austrian Head and Neck Cancer Society.

Anna Obenauf

Dr Obenauf is a leading expert in cancer biology and immunology. Her lab at the Research Institute of Molecular Pathology in Vienna conducts multi-disciplinary research into the molecular mechanisms underlying tumor progression and immune evasion with the goal of developing rational combination therapies for metastasic cancer. Dr Obenauf completed her PhD at the Medical University of Graz and conducted post-doctoral research at the Memorial Sloan Kettering Cancer Center in New York.

Anton Stütz

Professor Stütz is co-founder and co-CEO of Akribes Biomedical, which develops precision medicines for chronic wounds. He has more than 40 years experience in drug R&D and management, having established dermatology research at Sandoz/Novartis, where he invented the blockbuster drug terbinafine (Lamisil®). Professor Stütz holds a PhD in chemistry at the University of Vienna, and is the author of numerous publications and patents in fields ranging from synthetic and medicinal chemistry to immunology, inflammation and oncology. He has received national and international rewards for innovation in drug research and dermatology.

SUPERVISORY BOARD

Manfred Reichl, PhD, JD, MSc

Chairman

Entrepreneur, investor, business angel ("Austrian Business Angel of the Year 2009"), and Senior Adviser to renowned global institutions (e.g. UBS Investment Bank, World Economic Forum). More than 20 years of experience in international strategic consulting as Senior Managing Partner at Roland Berger, heading Austria and Eastern Europe for more than 15 years. European Program Manager for a Computer Line at Hewlett Packard. Lecturer in Vienna respectively Munich on "Corporate Governance", "China", and "Globalization".

Edward D. Charles

Board Member

A rounded finance professional, spending the first twenty years in banking where he was responsible for several derivatives trading books and then ran the European structured finance departments at J P Morgan, Credit Suisse and Bank of America. He has, in the last fifteen years, founded multiple financial businesses; including in the asset management, financial advisory and insurance underwriting arenas. For the last twenty years he has been a keen Private Equity investor in both the biotech and fintech industries and the Treasurer of Docklands Outreach, a London based charity. He holds a Masters from University College, Oxford in Politics, Philosophy and Economics and a Masters in Modern and Contemporary Literature from Birkbeck College, London.

Ulrich Granzer, PhD

Board Member

Independent consultant with currently 40 employees focusing on global drug development and regulatory affairs with special considerations for orphan drugs. Ulrich Granzer has major experience with biotech products and small molecules including orphan products.
He holds a PhD in pharmaceutical chemistry. Prior to being independent he held senior positions at Glaxo, BASF pharma Knoll, and Bayer.
He has a track record of working on more than 300 new molecular entities (small molecules, proteins incl. antibodies, oligonucleotides, gene therapies, cell therapies).

Erwin Rasinger, MD

Board Member

Austrian physician and politician. Studied Medicine and Business Administration in Vienna. Referee for ecology of the Medical Association of Austria. Member of Austrian National Assembly from 1994 until 2017.

Helmut Schuehsler, PhD

Board Member

Dr. Schuehsler led the creation of TVM Capital Healthcare in the United Arab Emirates in 2009, and in Singapore 2018, after he had joined the TVM Capital group of companies in Munich in 1990. Helmut has raised more than US$1bn in committed capital from more than 50 international investors, has overseen more than 120 investments in the health and life science market, and more than 50 IPOs and 30 M&A exit transactions.

Supervisory Board

Manfred Reichl, PhD, JD, MSc

Chairman